50 results about "Dysbacterioses" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses application of a bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-3-2 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for correcting intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-3-2 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, improve the level of serum markers in sarcopenia, regulate the homeostasis of intestinal flora so as to relieve muscular atrophy, prepare freeze-dried bacterial powder and enrich products for improving sarcopenia.

The invention relates to a dental and / or oral care product comprising between 0.0039% and 0.0078% by weight of nisin establishing and / or maintaining a pH of at least 4.5 in situ. Although said rather low nisin concentration does not provide an anti-bacterial effect, it is surprisingly and advantageously capable of maintaining stable pH values of at least 4.5, thereby preventing destruction of a subject's teeth enamel based on enamel demineralization effects at pH below 4.5, and said low nisin concentration advantageously further avoids dysbacteriosis, i.e. the oral microflora remains balanced, thus not leading to an increase of e.g. periodontitis associated bacteria.

The disclosure is directed to methods for culturing, transferring, and maintaining a microbiota containing a predominance of a select group of beneficial microorganisms to alleviate and / or treat gut dysbiosis, including gastrointestinal symptoms thereof, in a subject suffering from dysbiosis.

Provided herein are methods for preventing or treating antibiotic induced dysbiosis in a patient by administering to the subject a composition comprising a micro sphere, a bio film-generating probiotic bacterium and a prebiotic, wherein the prebiotic comprises a nutritional supplementation for the probiotic bacterium.

Provided herein are compositions comprising Escherichia coli (E. coli), Saccharomyces boulardii (S. boulardii), Lactobacillus plantarum (L. plantarum), and / or Ensifer meliloti (E. meliloti) and a first stabilizing excipient. Also provided herein are methods of delivering E. coli, S. boulardii, L. plantarum, and / or E. meliloti to a subject in need thereof, methods of inducing bacterial growth in a subject or in a cell, tissue, or biological sample, and methods of inhibiting an enteric pathogen in a subject or in a cell, tissue, or biological sample. Further provided herein are methods of treating dysbiosis in a subject in need thereof.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, comprising combinations or formulations of microbes, such as non-pathogenic, live bacteria and / or bacterial spores, for example as probiotics, for the control, amelioration, prevention, and treatment of a disease or condition, for example, a dysbiosis, or for augmenting the health or ability to thrive in an individual. In alternative embodiments, provided are compositions or formulations, including products of manufacture and kits, and methods, comprising at least one non-pathogenic, live bacteria and / or bacterial spore and at least one probiotic, or synbiotic. In alternative embodiment, these non-pathogenic, live bacteria and / or bacterial spores (and optionally also a probiotic) are administered to an individual in need thereof, thereby resulting in a modification or modulation of the individual's gut microfloral population(s).

The invention discloses a preparation method for constructing a mouse embryo implantation failure model based on fusobacterium variabilis, and belongs to the technical field of animal models. The method comprises the following steps: carrying out anaerobic culture on fusobacterium varium, giving the fusobacterium varium to a female C57 mouse through an intragastric administration way, continuously treating for 28 days, and inducing the female C57 mouse to have a phenotype that the number of implanted embryos is reduced and the expression of a vascular endothelial growth factor (VEGF) in a uterine tissue is reduced. According to the method, embryo implantation failure caused by intestinal flora imbalance is simulated through the'intestine-uterus axis' for the first time, a reliable animal model is provided for studying the causal relationship between flora and pregnancy failure, and the method has important scientific research and clinical application value.

Provided herein are pharmaceutical compositions comprising a bacterial population. The bacterial population comprises one bacterial strains or at least two bacterial strains. Such pharmaceutical compositions can be administered to a subject for prevention and / or treatment of dysbiosis and dysbiosis associated conditions and diseases, such as infant gastrointestinal diseases.

Oral composition comprising glutamate, or glutamine, solvate or hydrate thereof, for use in the treatment and / or prevention of caries, wherein the composition is orally administered and increases the pH of the saliva, reducing the risk of caries development. Said oral composition increases the amount of health-associated bacteria and / or decreases the amount of disease-associated bacteria and is useful for the treatment and / or prevention of oral diseases, such as periodontal diseases, halitosis and diseases caused by Candida. Method to determine the response of a mammal to the treatment with glutamate, or with glutamine, solvate or hydrate thereof, comprising determining in saliva the amount of health-associated or disease-associated bacteria or a dysbiosis index, and identifying the mammal as responsive or non-responsive to the treatment.

The present invention relates to a method for isolating and identifying a keystone microorganism in an ecosystem of interest. This keystone microorganism carries at least one metabolic function involved in an altered metabolic pathway in a representative sample of the ecosystem. This altered metabolic pathway is then responsible for dysbiosis.

The present invention is directed, inter alia, to compositions comprising a population of at least one strain of bacteria at least partially attached to particles, the particles comprise (i) a polysaccharide-based material; and (ii) a metal carbonate. Uses of the compositions, e.g., for prevention or treatment of dysbiosis, and methods for the preparation thereof are further provided herein.

The present application belongs to the technical field of microbial prevention and treatment, and particularly relates to a mycobacterium phage and application thereof. Specifically, the present application successfully screens a mycobacterium phage MP1 capable of precisely targeting and killing mycobacterium marinum, which can precisely target and kill specific mycobacterium marinum without causing adverse effects on normal flora. This feature enables the phage therapy to avoid the adverse reactions and flora imbalance problems caused by antibiotic treatment when treating drug-resistant mycobacterium marinum. Meanwhile, the above-mentioned mycobacterium phage MP1 is obtained from nature and is easy to be industrialized, and a drug or environmental disinfectant prepared from the above-mentioned phage not only can reduce the cost, but also has the advantages of green environmental protection and the like, and therefore has good practical application value.

The present invention relates to novel and stable preparations of bacterial extracts that exhibit considerably greater stability over time, to new methods of preparing them, to pharmaceutical formulations based on these new stabilized bacterial extracts, as well as to new routes of administration and delivery devices for the treatment and / or prevention of acute and chronic immunological disorders resulting from infections, inflammation, neoplasms, or dysbiosis.

The present invention relates to a composition for use in the prevention and / or treatment of dysbiosis. It also relates to the use of said composition for the preparation of a medicament for the prevention and / or treatment of dysbiosis. Furthermore, it relates to a method of preventing and / or treating dysbiosis wherein said composition is administered to a subject in need thereof.SOLUTION: A composition for use in the treatment and / or prevention of signs and / or symptoms associated with atopic dermatitis dysbiosis, xeroderma dysbiosis or oral aphthous dysbiosis, the composition comprising an olive product, trimethylglycine and xylitol, the composition comprising between 0.05% and 4.1% by weight of the olive product; A composition, wherein the olive product is olive oil and / or olive fruit extract; for use for the treatment of dysgeusia (taste disturbance or taste loss) associated with mucosal dysbiosis and / or pulmonary dysbiosis, or for the prevention of dehydration, dry cough and / or cold associated with dysbiosis, wherein the composition comprises an olive product, trimethylglycine and xylitol, wherein the composition comprises between 0.05% and 4.1% by weight of the olive product, and wherein the olive product is olive oil and / or olive fruit extract.SELECTED DRAWING: None

Provided herein are postbiotic compositions prepared using successive fermentation methods of specific bacteria and plant fiber material. Also provided herein are methods, including for the treatment or prevention of the disruption of gut microbiota, or dysbiosis, associated with an antibiotic treatment, chemotherapy treatment, or administration of a dysbiosis-causing medications or medical treatments, using said postbiotic compositions, or for improving responses and / or reducing complications to treatments such as antibiotics or chemotherapy. Such postbiotic compositions can also be used for the treatment or prevention of the disruption of the gut-brain axis, including to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.

A microbiome modulating composition and a method for producing the microbiome modulating composition are described herein. The method comprises preparing a culture from at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, passaging the culture on a glycogen carbon source to form a postbiotic ferment of the at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, and adding the postbiotic ferment to a carrier. Further disclosed is a method for treating microbial dysbiosis of an urogenital area or a skin area of a user, the method comprising applying the microbiome modulating composition to an urogenital or a skin area of a user. The disclosed methods and microbiome modulating compositions help promote the growth of healthy Lactobacillus spp. bacteria to prevent dysbiosis and other related conditions and infections.

Provided herein are bacterial compositions that are useful for treating and preventing complications and side effects associated with a disease or disorder, such as those associated with dysbiosis of a gastrointestinal tract. The bacterial compositions disclosed herein are designed to exhibit one or more functional features that are useful for the treatment of such diseases and disorders.

The invention discloses a microecological preparation capable of regulating and controlling abundance of intestinal bifidobacteria in a targeted mode and application of the microecological preparation, the microecological preparation is composed of intestinal symbiotic bacteria and prebiotics, the intestinal symbiotic bacteria are bacteroides, and the prebiotics are polysaccharide containing N-acetylglucosamine. The prebiotics and the bacteroides multiforme CCFM1441 are combined for use, the prebiotics N-acetylglucosamine can be effectively released, nutrition is provided for bifidobacterium longum, and proliferation of the bifidobacterium longum is promoted. Further, in vitro and in vivo experiments prove that there is a strong cross-feeding activity between Bacteroides multiforme CCFM1441 and Bifidobacterium longum based on prebiotics. The beneficial microecological preparation can promote proliferation of bifidobacterium longum in intestinal tracts in a targeted manner, improves intestinal flora imbalance caused by antibiotics, and further has a huge application prospect in preparation of products (such as food, drugs or health care products) for improving intestinal health.

A programmable drug-delivery system comprising a chassis cell, (e.g., a Molecularly Encoded Memory via an Orthogonal Recombinase arraY (MEMORY)) engineered to produce an orthogonal inducible recombinase to alter extrachromosomal nucleic acid. Also disclosed herein is a synthetic probiotic composition comprising the programmable drug-delivery system, described herein, and a pharmaceutically acceptable carrier, and the methods of use thereof in preventing or treating gut microbiota dysbiosis in a subject in need thereof.

The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and / or dysbiosis.

The invention discloses a preparation method of a ficus microcarpa extract and application of the ficus microcarpa extract in intestinal flora disorder caused by circadian rhythm disorder. Pharmacological experiments prove that the ficus striata flavone has a remarkable regulating effect in a circadian rhythm disorder injury model: the ficus striata flavone can be used for effectively solving the problems that the diversity of intestinal flora is reduced, the excessive propagation of firmictures, the expression of Bacteroidetes is reduced and the like, which are caused by circadian rhythm disorder, and can be used for preventing and treating the diseases caused by circadian rhythm disorder, so that the ficus striata flavone can be used for preventing and treating the diseases caused by circadian rhythm disorder. Meanwhile, circadian rhythm oscillation of key bacteria such as prevotella, Bacteroides and Clostridium can be adjusted, and increase of the F / B ratio is reduced, so that the rhythm and stability of intestinal flora are improved. The invention simultaneously discloses two preparation processes, namely an ethanol reflux-resin purification method and a water extraction-concentration-alcohol precipitation method, so that the stable quality of the extract is ensured, and the industrial feasibility is realized.

In alternative embodiments, compositions, e.g., articles of manufacture and kits, and methods are provided that include combinations or formulations of microorganisms, e.g., live non-pathogenic bacteria and / or bacterial spores, e.g., as probiotics, for the control, amelioration, prevention, and treatment of diseases or conditions, e.g., dysbiosis, or to increase the health or developmental capacity of an individual. In alternative embodiments, compositions or formulations, e.g., articles of manufacture and kits, and methods are provided that include at least one live non-pathogenic bacteria and / or bacterial spore and at least one probiotic or synbiotic. In alternative embodiments, these live non-pathogenic bacteria and / or bacterial spores (and optionally probiotics) are administered to an individual in need thereof, thereby resulting in the alteration or modulation of the individual's intestinal microflora population.

The invention belongs to the technical field of microbial control, and particularly relates to a mycobacterium marinum bacteriophage and application thereof. Specifically, the mycobacteriophage MP1 capable of accurately targeting and killing mycobacterium marinum is successfully screened, and the mycobacteriophage MP1 can accurately target and kill specific mycobacterium marinum without generating adverse effects on normal flora. Due to the characteristic, when the bacteriophage therapy is used for treating the drug-resistant mycobacterium marinum, the problems of adverse reaction and dysbacteriosis caused by antibiotic treatment are avoided. Meanwhile, the mycobacteriophage MP1 is obtained from the nature and is easy to industrially produce, and the medicine or the environmental disinfectant prepared from the mycobacteriophage can reduce the cost and has the advantages of being green, environmentally friendly and the like, so that the mycobacteriophage MP1 has good practical application value.

Methods and compositions for modulating a microbiome of a urogenital area or a skin area of a user are disclosed. The method can include applying a composition to a urogenital area or a skin area of a user, wherein the composition can include a carrier and a therapeutic agent. The therapeutic agent can include at least one prebiotic comprising at least one high molecular weight dextrin with two or more α-1,6-glycosidic bonds, with or without a cyclic moiety. The at least one high molecular weight dextrin with two or more α-1,6-glycosidic bonds comprises a highly branched cyclic dextrin, a β-limit dextrin, or a combination thereof. The method can further include promoting a healthy microflora balance of the urogenital area or the skin area of the user. Further disclosed is a composition for modulating a microbiome of a urogenital area or a skin area of a user, wherein the composition comprises a single liquid phase, the single liquid phase comprising an aqueous solution and a therapeutic agent. The therapeutic agent can include at least one prebiotic compound comprising at least one high molecular weight dextrin with two or more α-1,6-glycosidic bonds, with or without a cyclic moiety, such as a highly branched cyclic dextrin, a β-limit dextrin, or a combination thereof. The disclosed methods and compositions for modulating a microbiome of a urogenital area or a skin area of a user help promote the growth of healthy Lactobacillus species to prevent dysbiosis and other related conditions and infections.

The invention provides an antibacterial peptide as well as a screening method and application thereof. On the first aspect, the invention provides the antibacterial peptide, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO. 1. The antibacterial peptide has high specificity on staphylococcus aureus in a certain concentration range, has no inhibition effect on other common skin symbiotic bacteria such as staphylococcus epidermidis, staphylococcus vorus and propionibacterium acnes, can avoid damage to normal flora balance of a human body, reduces the risk of secondary infection, and has a good application prospect. The problem of flora imbalance caused by broad-spectrum killing of the existing antibacterial peptide is solved. In addition, the minimum inhibitory concentration on staphylococcus aureus is low, the obvious bacteriostatic effect can be achieved under the condition of lower dosage, and the medicine dosage and potential side effects are reduced. In addition, the compound is derived from human skin symbiotic microorganisms and has good biocompatibility with the human body, in-vitro cytotoxicity experiments prove that the effective antibacterial concentration of the compound has no obvious toxicity on human skin keratinocytes, and the safety of the compound is superior to that of chemically synthesized antibacterial molecules.

A method of treating or preventing urobiome dysbiosis in a subject in need thereof is described. The method includes intravesicularly administering to the subject a therapeutically effective amount of two or more of an antimicrobial agent, and antispasmodic agent, and a live biotherapeutic product (LBP). Additional methods of determining the likelihood of symptomatic urinary tract infection (UTI) in a subject and selecting treatment for a UTI in a subject are described, as well as Live Biotherapeutic Product (LBP) compositions and the use thereof in methods for the treatment and / or prevention of UTI in a subject.

The application discloses an oral immune system with a cascade response characteristic as well as a preparation method and application thereof, and belongs to the technical field of biological medicine and nano-preparation. The oral immune system comprises, from inside to outside, a core layer, an intermediate modification layer, a functional unit and a protective shell. The core layer is a live rumen coccus outer membrane vesicle. The intermediate modification layer is a polydopamine coating layer coated on the surface of the core layer. The functional unit is a cerium nanoscale enzyme covalently connected to the surface of the polydopamine coating layer through a thio-ketal bond connecting arm. The protective shell is made of calcium carbonate. The oral immune system integrates oral delivery barrier breakthrough, inflammation microenvironment responsiveness antioxidant and pathogenic bacteria specific immune clearance in the same platform, can break the vicious cycle of flora imbalance, oxidative stress and barrier damage in cooperation, and reduces the interference on beneficial symbiotic flora.